Analysts have been eager to weigh in on the Healthcare sector with new ratings on Harmony Biosciences Holdings (HRMY – Research Report) and Indivior (GB:INDV – Research Report).

Harmony Biosciences Holdings (HRMY)

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on Harmony Biosciences Holdings on February 3 and set a price target of $31.00. The company’s shares closed last Thursday at $34.89.

According to TipRanks.com, Gerberry is a 3-star analyst with an average return of 1.4% and a 44.6% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Arrowhead Pharmaceuticals, and Intra-Cellular Therapies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Harmony Biosciences Holdings with a $51.71 average price target.

Indivior (GB:INDV)

Stifel Nicolaus analyst Christian Glennie maintained a Buy rating on Indivior yesterday and set a price target of p1100.00. The company’s shares closed last Friday at p700.39, close to its 52-week low of p555.00.

Glennie has an average return of 19.1% when recommending Indivior.

According to TipRanks.com, Glennie is ranked #8869 out of 9389 analysts.

Currently, the analyst consensus on Indivior is a Strong Buy with an average price target of p1222.51, implying a 65.2% upside from current levels. In a report issued on February 12, Craig-Hallum also maintained a Buy rating on the stock.